Results 131 to 140 of about 47,826 (189)

A review of the current evidence for maintenance therapy in gastric cancer. [PDF]

Front Pharmacol
Han X, Zhang Y, Fan Q, Yu J, Lv L, Li Y, Hou L.   +6 more
europepmc   +1 more source

Efficacy and Safety of Envafolimab Combined With Capecitabine and Lenvatinib as Postoperative Adjuvant Therapy in Resected Biliary Tract Cancer With High-Risk Recurrence Factors: A Phase II Single-Center Prospective Study. [PDF]

Cancer Med
Tian Y, Lei T, Ruan Q, Zhou X, Shen R, Xie T, Li S, Cai X, Chen M.   +8 more
europepmc   +1 more source

Real-World Effectiveness and Safety of Tucatinib, Trastuzumab, and Capecitabine in HER2-Positive Advanced Breast Cancer: A Multicenter Portuguese Study. [PDF]

Eur J Breast Health
Ferreira RQ, Monteiro CB, Dias AC, Abreu F, Darmits B, Oura MJ, Ângelo I, Cabral J, Figueiredo A, Ferreira R, Alpuim Costa D, Marques MT, Pina-Cabral T, Araújo F, Bento S, Fernandes CL, Santiago M, Silva B, Montenegro MA, Simão DC, Fernandes L, Oliveira SD.   +21 more
europepmc   +1 more source

Advances in the study of pyrotinib for the treatment of HER2-positive breast cancer. [PDF]

Breast Cancer Res
Li Y, Wang W, Liang Y, Lai H, Mi K, Zhang P, Zhang J, Wang Y.   +7 more
europepmc   +1 more source

Preoperative Chemoradiotherapy with Tegafur-Uracil, Capecitabine, or 5-Fluorouracil/Leucovorin for Rectal Cancer in an Asian Cohort: A Real-World Comparison from the Pre-TNT Era. [PDF]

Curr Oncol
Dai KY, Chen FY, Liu CK, Lin J, Liu SH.
europepmc   +1 more source

Efficacy of Ninjin'yoeito in Adjuvant Chemotherapy for Colorectal Cancer: A Retrospective Clinical Study with Propensity Score Matching Analysis. [PDF]

J Anus Rectum Colon
Kasahara K, Mazaki J, Sujino H, Kuboyama Y, Udo R, Tago T, Osakabe H, Kuwabara H, Iwasaki K, Koga H, Kanazawa A, Nagakawa Y.   +11 more
europepmc   +1 more source

Fosnetupitant for long-delayed chemotherapy-induced nausea and vomiting in oxaliplatin-based regimens: a prospective observational study (LODEC-N). [PDF]

Cancer Chemother Pharmacol
Iimura Y, Iihara H, Aoyama T, Hayashi T, Ishibashi M, Sasuga C, Furukawa N, Anzai E, Ijichi Y, Kuroda S.   +9 more
europepmc   +1 more source

Developing and evaluating definitions of real-world clinical endpoints for patients with early-stage triple-negative breast cancer using a United States of America secondary database. [PDF]

ESMO Real World Data Digit Oncol
Hu X, Earla JR, Cruz GI, Mohammed H, Privette T, Hernandez A, Krishnan R, Pan W, Haiderali A.   +8 more
europepmc   +1 more source

Pancreatic ductal adenocarcinoma with ITSN1-ALK fusion: sustained response to alectinib with 19-month progression-free survival. [PDF]

Oncologist
Liu C, Wang X, Chen L.
europepmc   +1 more source

DESTINY-Breast08: A Phase Ib Study of Trastuzumab Deruxtecan in Combination with Other Anticancer Therapies in Patients with HER2-Low Metastatic Breast Cancer. [PDF]

Clin Cancer Res
Jhaveri K, Loi S, Hamilton E, Schmid P, Anders CK, Testa L, Wildiers H, Tseng LM, Lu YS, Park YH, Im SA, Chen SC, Young RR, Lloyd C, Wrona M, Zhang C, Carroll D, André F.   +17 more
europepmc   +1 more source